Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-07-05
2005-07-05
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S093100, C435S007320, C435S069100
Reexamination Certificate
active
06913750
ABSTRACT:
A protein construct comprising a pilus protein portion, preferably a structurally stabilized pilus-protein, and an additional, or effector, portion other than a pilus protein or chaperone and wherein said effector portion serves to stabilize the pilus protein portion and to confer a therapeutic activity, such as vaccine activity or anti-microbial or anticancer activity, on the protein construct is disclosed. Such effector portion commonly comprises a donor strand complementary segment capable of structurally stabilizing a pilus protein subunit and attaching the auxiliary portion to said subunit to form the pilus protein analog of the invention. Methods of using said protein constructs are also disclosed as well as the formation and use of analogs comprising fragments of a pilus protein linked to effector components to produce immunogenic and/or therapeutic activity.
REFERENCES:
patent: 6500434 (2002-12-01), Langermann et al.
patent: WO 95/20657 (1995-08-01), None
patent: WO 01/04148 (2001-01-01), None
Jones et al. Proc. Natl. Acad. Sci., vol. 90, pp. 8397-8401, Sep. 1993.
Jones et al. Proc. Natl. Acad. Sci., vol. 92, pp. 2081-2085, Mar. 1995.
Thankavel et al. Journal of Clinical Investigation, vol. 100, No. 5, pp. 1123-1126, Sep. 1997.
Herren et al. Proc. Natl. Acad. Sci., vol. 95, pp. 6037-6042, May 1998.
Langermann et al. Science., vol. 276, pp. 607-611, Apr. 1997.
Sauer et al. Science., vol. 285, pp. 1058-1061, Aug. 1999.
Kuehn et al. Science., vol. 262, pp. 1234-1241, Nov. 1993.
Saulino et al. Proc. Natl. Acad Sci. vol. 97, pp. 9240-245, Aug. 2000.
Sauer, et al., “Structural Basis of Chaperone Function and Pilus Biogenesis,” Science, vol. 285, pp. 1058-1061 (Aug. 1999).
Barnhart, et al., “PapD-like chaperones provide the missing information for folding of pilin proteins,” PNAS, vol. 97, No. 14 (Jul. 5, 2000).
Choudhury, et al., “X-ray Structure of the FimC-FimH Chaperone-Adhesin Complex from UropathogenicEscherichia coli, ” Science, vol. 285, pp. 1061-1066 (Aug. 13, 1999).
Langermann, et al., “Prevention of MucosalEscherichia coliInfection by FimH-Adhesin-Based Systemic Vaccination,” Science, vol. 276, pp. 607-611 (Apr. 25, 1997).
Joens, et al., “FimC is a periplasmic PapD-like chaperone that directs assembly of type I pili in bacteria,” Proc. Nat'l. Acad. Sci. USA, vol. 90, pp. 8397-8401 (Sep. 1993).
Hung, et al., “Molecular basis of two subfamilies of immunoglobulin-like chaperones,” EMBO Journal, vol. 15, No. 15, pp. 3792-3805 (1996).
Hultgren, et al., “The PapG adhesin of uropathogenicEscherichia colicontains separate regions for receptor binding and for the incorporation into the pilus,” Proc. Nat'l. Acad. Sci, USA, vol. 86, pp. 4357-4361 (Jun. 1989).
Knight, et al., “Crystallization and preliminary X-ray diffraction studies of the FimC-FimH chaperone-adhesin complex fromEscherchia coli,” Acta Crystallographica, Section D, pp. 207-210 (1997).
Saulino, et al., “Ramifications of kinetic partitioning on usher-mediated pilus biogenesis,” EMBO Journal, vol. 17, No. 8, pp. 2177-2185 (1998).
Bereneice McClentton Madison, “Structural, Antigenic and Functional Analysis of FIMH Protein inEscherichia ColiandKlebsiella PneumoniaeType 1 Fimbriae,” Univ. of Tennesse Cntr. for the Health Sciences, vol. 52/06-B, p. 2893, 159 pages (1990).
“Abstracts of the 89th Annual Meeting of the American Society for Microbiology,” New Orleans, La, May 14-18, 1989.
Tewari, et al., “Neutrophil Activation by Nascent FimH Subunits of Type 1 Fimbriae Purified from the Periplasm ofEscherichia coli, ” Journal of Biological Chemistry, vol. 268, No. 4, pp. 3009-3015 (1993).
Palaszynski et al, inModulation of the Immune Response to Vaccine Antigens, vol. 92, pp 117-122 (1998).
Thankavel, et al., “Localization of a Domain in the FimH Adhesin ofEscherichia coliType 1 Fimbriae Capable of Receptor Recognition and use of a Domain-specific Antibody to Confer Protection against Experimental Urinary Tract Infection,” American Society for Clinical Investigation, vol. 100, No. 5, pp. 1123-1136 (Sep. 1997).
Abraham, et al., “Conservation of the D-Mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae,” Nature, vol. 336 (Dec. 1988).
Abraham, et al., Protection AgainstEscherichia coli-Induced Urinary Tract Infections with Hybridoma Antibodies Directed Against Type 1 Fimbriae or Complementary D-Mannose Receptors, Infection and Immunity, vol. 48, No. 3, pp. 625-628 (Jun. 1985).
Hanley, et al., “Molecular Basis ofEscherichia coliColonization of the Upper Urinary Tract in BALB/c Mice,” Amer. Society for Clinical Investigation, Inc., vol. 75, pp. 347-360 (Feb. 1985).
Langermann et al., J. Infectious Dis., vol. 181, pp. 774-778 (2000).
Langermann et al., J. Infectious Dis., vol. 183, Suppl., pp. S84-S86 (2001).
Dodson et al, PNAS (USA), vol. 90, pp. 3670-3674 (1993).
Hultgren Scott J.
Langermann Solomon
Sauer Frederic G.
Grant Alan J.
MedImmune, Inc.
Olstein Elliot M.
Shahnan-Shah Khatol S
Swartz Rodney P
LandOfFree
Therapeutic compounds structurally-linked to bacterial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds structurally-linked to bacterial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds structurally-linked to bacterial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3408716